Detalles de la búsqueda
1.
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: A single-arm, open-label, phase 2, multicenter study.
Am J Hematol
; 98(10): 1579-1587, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37466271
2.
[The Relationship between PPP2R5C and Molt-4 Cell Viability, HSP90-GR Signal in Childhood Acute T Lymphocytic Leukemia].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
; 30(1): 84-91, 2022 Feb.
Artículo
en Zh
| MEDLINE | ID: mdl-35123608
3.
[Expression Level of SOCS3 in Acute Lymphoblastic Leukemia Cells Affects the Cytotoxicity of NK Cells].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
; 30(2): 400-406, 2022 Apr.
Artículo
en Zh
| MEDLINE | ID: mdl-35395970
4.
Chronic disease management practices and factors associated with health-related quality-of-life for persons with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.
Ann Palliat Med
; 11(4): 1336-1350, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35523742
5.
[Prognostic Factors and Predictive Value of MRD before Consolidation Therapy in Middle-risk Newly Diagnosed Young and Middle-aged Patients with AML].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
; 29(2): 462-468, 2021 Apr.
Artículo
en Zh
| MEDLINE | ID: mdl-33812416
6.
[Clinical Efficacy and Prognostic Factors of Newly Diagnosed Children[JP] with Burkitt Lymphoma Treated by High-Dose and Short-Course Modified LMB Regimen ± Rituximab].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
; 28(2): 529-534, 2020 Apr.
Artículo
en Zh
| MEDLINE | ID: mdl-32319391
7.
[Change of Autophagic Activity of U266 Cells after Bortezomib -Resistance and Its Mechanisms].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
; 27(1): 129-133, 2019 Feb.
Artículo
en Zh
| MEDLINE | ID: mdl-30738459
8.
[Reversal Effect of Pioglitazone on Multidrug Resistance in K562/ADR Cells and Its Mechanism].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
; 27(3): 785-789, 2019 Jun.
Artículo
en Zh
| MEDLINE | ID: mdl-31204932
Resultados
1 -
8
de 8
1
Próxima >
>>